Search results

  1. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    Recommendation ID NG188/2 Question What are the most clinically effective interventions (including social prescribing and structured community

  2. Evidence on the safety and efficacy of balloon cryoablation for squamous dysplasia of the oesophagus is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. This could be in the form of randomised controlled trials or published registry data.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG683/1 Question Evidence on the safety and efficacy of balloon cryoablation for squamous dysplasia of the oesophagus

  3. Evidence on the safety and efficacy of balloon cryoablation for Barrett's oesophagus is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research. This could be in the form of randomised controlled trials or published registry data.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG682/1 Question Evidence on the safety and efficacy of balloon cryoablation for Barrett's oesophagus is inadequate

  4. Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent but potentially serious adverse events: For people who need to lose weight in the short term for medical reasons, the evidence of efficacy is adequate to support the use of this procedure provided that special arrangements are in place for clinical governance, consent and audit.  Find out  what special arrangements mean on the NICE interventional procedures guidance page . For people who are aiming for long-term weight loss, the evidence on efficacy is inadequate in quantity and quality, so the procedure should only be used in the context of research.   Find out  what only in research means on the NICE interventional procedures guidance page .

    Recommendation ID IPG684/1 Question Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent

  5. Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis shows that this procedure can cause serious but well-recognised side effects. Evidence on its efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out what  only in research means on the NICE website .

    Recommendation ID IPG681/1 Question Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis

  6. Develop and validate new and existing screening tools (including physical, psychological and psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools are validated for screening for post‑COVID‑19 syndrome, which are the most accurate at identifying post‑COVID‑19 syndrome in a UK population and what is their effectiveness in guiding management?

    Recommendation ID NG188/7 Question Develop and validate new and existing screening tools (including physical, psychological and

  7. Early and locally advanced breast cancer

    Everything NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

  8. Acutely ill patients in hospital

    Everything NICE has said on recognising and responding to acute illness in adults in hospital in an interactive flowchart

  9. Urinary incontinence in neurological disease

    Everything NICE has said on managing lower urinary tract dysfunction resulting from neurological disease and injury in an interactive flowchart

  10. Diabetes in children and young people

    Everything NICE has said on diagnosing and managing type 1 and 2 diabetes in children and young people in an interactive flowchart

  11. Type 1 diabetes in adults

    Everything NICE has said on diagnosing and managing type 1 diabetes in adults in an interactive flowchart

  12. Type 2 diabetes in adults

    Everything NICE has said on managing type 2 diabetes in adults in an interactive flowchart

  13. Pancreatitis

    Everything NICE has said on pancreatitis in an interactive flowchart

  14. Eating disorders

    Everything NICE has said on identifying and managing eating disorders in people 8 years and over in an interactive flowchart

  15. Preventing type 2 diabetes

    Everything NICE has said on preventing type 2 diabetes in an interactive flowchart

  16. Parkinson's disease

    Everything NICE has said on diagnosing and managing Parkinson's disease in adults in primary and secondary care in an interactive flowchart

  17. Chronic kidney disease

    Everything NICE has said on chronic kidney disease (renal failure) in an interactive flowchart

  18. Nutrition support in adults

    Everything NICE has said on nutrition support for adults who are malnourished or at risk of malnutrition in an interactive flowchart

  19. Food allergy in under 19s

    Everything NICE has said on diagnosing and assessing food allergy in children and young people in primary care and community settings in an interactive flowchart

  20. Transient loss of consciousness

    Everything NICE has said on assessing, diagnosing and referring adults and young people who have experienced a blackout in an interactive flowchart

  21. Leg ulcers

    Everything NICE has said on leg ulcers in an interactive flowchart

  22. Antimicrobial stewardship

    Everything NICE has said on effective antimicrobial medicine use and preventing the spread of resistant microbes in an interactive flowchart

  23. Upper aerodigestive tract cancer

    Everything NICE has said on assessing and managing upper aerodigestive tract cancer in young people and adults in an interactive flowchart

  24. Prostate cancer

    Everything NICE has said on diagnosing and treating prostate cancer in an interactive flowchart

  25. Drug misuse management in over 16s

    Everything NICE has said on psychosocial interventions and opioid detoxification for drug misuse in an interactive flowchart

  26. Drug allergy

    Everything NICE has said on diagnosing and managing drug allergy in an interactive flowchart

  27. Spasticity in children and young people

    Everything NICE has said on managing spasticity and co-existing motor disorders in children and young people in an interactive flowchart

  28. Ectopic pregnancy and miscarriage

    Everything NICE has said on diagnosing and managing tubal ectopic pregnancy and miscarriage in early pregnancy in an interactive flowchart.

  29. The percentage of patients registered at the practice aged 65 years and over who have been diagnosed with one or more of the following conditions: coronary heart disease, heart failure, hypertension, diabetes, CKD, PAD, or stroke/TIA who have had a pulse rhythm assessment in the preceding 12 months.

    The percentage of patients registered at the practice aged 65 years and over who have been diagnosed with one or more of the following conditions:...

  30. The percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if ACE-I intolerant), aspirin (or clopidogrel) (or anticoagulant drug therapy) and a statin and a beta-blocker for those patients with left ventricular systolic dysfunction

    The percentage of patients with a history of myocardial infarction (more than 12 months ago) who are currently being treated with an ACE-I (or ARB if...

  31. The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)

    The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring...

  32. The percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with ACE-I (or ARB if ACE-I intolerant), dual anti-platelet therapy, a statin and a beta blocker for those patients with left ventricular systolic dysfunction

    The percentage of patients who had a myocardial infarction in the preceding 1 April to 31 March and who are currently being treated with ACE-I (or ARB